bioRxivMicrobiologyPreprint
An AAV-ie based Vaccine effectively protects against SARS-CoV-2 and Circulating Variants
S. Zhao, F. Tan, J. Ke, J. Yang, C.-b. Lin, H. Wang, g. zhong
Abstract
Prophylactic vaccines against SARS-CoV-2 have been extensively developed globally to overcome the COVID-19 pandemic. However, recently emerging SARS-CoV-2 variants B.1.1.7 and B.1.351 limit the vaccine protection effects and successfully escape antibody cocktail treatment. Herein, based on our previously engineered adeno-associated viral (AAV) vector, AAV-ie, and systematic immunogen screening, we developed an AAV-ie-S1 vaccine with thermostability, high efficiency, safety, and single-dose vaccination advantage. Importantly, the AAV-ie-S1 immune sera efficiently neutralize B.1.1.7 and B.1.351, indicating a potential to circumvent the spreading of SARS-CoV-2.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Single-shot rAAV5-based Vaccine Provides Long-term Protective Immunity against SARS-CoV-2 and Its Variants
- Vectored Immunoprophylaxis and Treatment of SARS-CoV-2 Infection
T. Tada, B. M. Dcosta, … N. R. Landau·bioRxiv·Jan 11, 2023
- Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques
- Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates
N. Zabaleta, W. Dai, … L. H. Vandenberghe·bioRxiv·Jan 5, 2021
- A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine
S. Jangra, J. J. Landers, … P. T. Wong·bioRxiv·Feb 18, 2021
- mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
T. L. Darling, B. Ying, … A. Boon·bioRxiv·Dec 29, 2021